Hotgen provides a multi‑omics diagnostic platform that combines magnetic‑particle chemiluminescence, exosome capture, and DNA‑methylation assays to deliver high‑sensitivity biomarker measurements from a single sample. The company also offers handheld, automated analyzers for point‑of‑care testing and leverages the same technology to develop antibody and nucleic‑acid therapeutics, such as the SGC001 myocardial‑infarction antibody.
Funding
Funding not disclosed
Founders
Product
Problem
Healthcare providers and researchers often lack integrated, high‑sensitivity diagnostic tools that can simultaneously assess protein markers, glycan‑modified exosomes, and DNA methylation patterns, limiting early detection and precise monitoring of complex diseases. Additionally, there is a shortage of rapidly developable therapeutic candidates such as antibody and nucleic‑acid drugs for acute conditions like myocardial infarction.
Solution
Hotgen develops a multi‑omics diagnostic platform that combines magnetic‑particle chemiluminescence, exosome capture technologies, and DNA‑methylation assays to deliver quantitative, high‑throughput biomarker measurements from a single sample. The company also offers portable, automated analyzers (e.g., UPT series) that enable point‑of‑care testing with minimal operator training. Leveraging the same technology base, Hotgen advances therapeutic pipelines, including antibody and nucleic‑acid drugs such as the SGC001 myocardial‑infarction antibody, which has progressed to IND filing and Phase II trials. By integrating diagnostics and drug development, Hotgen aims to shorten the time from biomarker discovery to clinical intervention.
Target Audience
Primary customers are clinical laboratories, hospitals, and research institutions that require comprehensive biomarker testing, as well as pharmaceutical companies seeking partner platforms for antibody and nucleic‑acid drug development.
Features
- Magnetic‑particle chemiluminescence assays for ultra‑sensitive protein biomarker detection
- Glycan‑targeted exosome capture and analysis enabling extracellular vesicle‑based diagnostics
- DNA‑methylation profiling panels for epigenetic disease markers
- Handheld, automated UPT analyzers (e.g., UPT‑3A 1200, UPT‑2800) for rapid point‑of‑care testing
- Integrated data management platform that consolidates multi‑omics results for clinical interpretation
- Antibody drug development pipeline with IND‑ready candidates (e.g., SGC001)
- Nucleic‑acid therapeutic platform supporting antisense and RNA‑based drug candidates